{"disease":{"id":"respiratory-syncytial-virus-immunization","name":"respiratory syncytial virus immunization"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT06185647","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","phase":"","overall_status":"COMPLETED","enrollment_count":4924,"lead_sponsor_name":"Hôpital Armand Trousseau","has_results":false},{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT06824207","title":"Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06686654","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1530,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05639894","title":"Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":865,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07071558","title":"Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Sanofi","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}